Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 2
2008 3
2009 1
2010 1
2011 1
2012 3
2013 3
2015 3
2016 2
2017 3
2018 3
2019 2
2020 3
2021 1
2022 1
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Enhanced detection of circulating tumor DNA by fragment size analysis.
Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K, Wan JCM, Supernat A, Hudecova I, Gounaris I, Ros S, Jimenez-Linan M, Garcia-Corbacho J, Patel K, Østrup O, Murphy S, Eldridge MD, Gale D, Stewart GD, Burge J, Cooper WN, van der Heijden MS, Massie CE, Watts C, Corrie P, Pacey S, Brindle KM, Baird RD, Mau-Sørensen M, Parkinson CA, Smith CG, Brenton JD, Rosenfeld N. Mouliere F, et al. Among authors: ros s. Sci Transl Med. 2018 Nov 7;10(466):eaat4921. doi: 10.1126/scitranslmed.aat4921. Sci Transl Med. 2018. PMID: 30404863 Free PMC article.
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Lawson M, Cureton N, Ros S, Cheraghchi-Bashi A, Urosevic J, D'Arcy S, Delpuech O, DuPont M, Fisher DI, Gangl ET, Lewis H, Trueman D, Wali N, Williamson SC, Moss J, Montaudon E, Derrien H, Marangoni E, Miragaia RJ, Gagrica S, Morentin-Gutierrez P, Moss TA, Maglennon G, Sutton D, Polanski R, Rosen A, Cairns J, Zhang P, Sánchez-Guixé M, Serra V, Critchlow SE, Scott JS, Lindemann JPO, Barry ST, Klinowska T, Morrow CJ, Carnevalli LS. Lawson M, et al. Among authors: ros s. Cancer Res. 2023 Dec 1;83(23):3989-4004. doi: 10.1158/0008-5472.CAN-23-0694. Cancer Res. 2023. PMID: 37725704 Free PMC article.
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, Urosevic J, Carnevalli LS, Talbot S, Bradshaw L, Blaker C, Gunda S, Owenson V, Hoffmann S, Sutton D, Jones S, Goodwin RJA, Willis BS, Rooney C, de Bruin EC, Barry ST. Hopcroft L, et al. Among authors: ros s. NPJ Breast Cancer. 2023 Aug 5;9(1):64. doi: 10.1038/s41523-023-00571-w. NPJ Breast Cancer. 2023. PMID: 37543694 Free PMC article.
Pancreatic nesidioblastosis: Case report.
Allué M, Ros S, Lamata F. Allué M, et al. Among authors: ros s. Med Clin (Barc). 2019 Mar 15;152(6):245-246. doi: 10.1016/j.medcli.2018.06.009. Epub 2018 Aug 20. Med Clin (Barc). 2019. PMID: 30139587 English, Spanish. No abstract available.
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation.
Erickson EC, You I, Perry G, Dugourd A, Donovan KA, Crafter C, Johannes JW, Williamson S, Moss JI, Ros S, Ziegler RE, Barry ST, Fischer ES, Gray NS, Madsen RR, Toker A. Erickson EC, et al. Among authors: ros s. Sci Signal. 2024 Feb 27;17(825):eadf2670. doi: 10.1126/scisignal.adf2670. Epub 2024 Feb 27. Sci Signal. 2024. PMID: 38412255 Free PMC article.
Characterization of full-length p53 aggregates and their kinetics of formation.
Julian L, Sang JC, Wu Y, Meisl G, Brelstaff JH, Miller A, Cheetham MR, Vendruscolo M, Knowles TPJ, Ruggeri FS, Bryant C, Ros S, Brindle KM, Klenerman D. Julian L, et al. Among authors: ros s. Biophys J. 2022 Nov 15;121(22):4280-4298. doi: 10.1016/j.bpj.2022.10.013. Epub 2022 Oct 13. Biophys J. 2022. PMID: 36230002 Free PMC article.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, Urosevic J, Carnevalli LS, Talbot S, Bradshaw L, Blaker C, Gunda S, Owenson V, Hoffmann S, Sutton D, Jones S, Goodwin RJA, Willis BS, Rooney C, DeBruin E, Barry ST. Hopcroft L, et al. Among authors: ros s. NPJ Breast Cancer. 2023 Aug 18;9(1):69. doi: 10.1038/s41523-023-00575-6. NPJ Breast Cancer. 2023. PMID: 37596288 Free PMC article. No abstract available.
35 results